Article Data

  • Views 1741
  • Dowloads 141

Original Research

Open Access

Quality of life in lung cancer patients due to treatment


1General Hospital Gradiška, Gradiška, Bosnia and Herzegovina

2University Clinical Centre Banja Luka, Banja Luka, Bosnia and Herzegovina

DOI: 10.22514/SV112.062016.10 Vol.11,Issue S2,June 2016 pp.47-50

Published: 14 June 2016

*Corresponding Author(s): BRANKA MILOŠEVIĆ E-mail:


Lung cancer is the second most common cancer in men and women. Survival has not significantly improved despite new therapeutic possibilities. Therefore, in pa-tients with end-stage disease, the primary goal is to preserve the quality of life as long as possible.

The study included patients divided into four groups depending on the treatment: treated with chemotherapy, radiotherapy, a combination of chemotherapy and radio-therapy and patients treated with sympto-matic therapy. Each group consists of 30 subjects. We measured quality of life using a questionnaire of the European Associa-tion for the Study and Treatment of Cancer in addition of no.13 for lung cancer (EO-RTC QLQ C30 + LC13), which is validated and translated in the native language and includes 43 questions.

Patients who are on symptomatic therapy have the worst quality of life, and all as-pects of normal functioning are the most disturbed when compared to patients treated with other therapeutic modalities. Quality of life is best for patients who are treated with chemotherapy. Any modality of treatment, especially chemotherapy, is superior to the use of only symptomatic treatment. 


lung cancer, quality of life, chem-otherapy

Cite and Share

BRANKA MILOŠEVIĆ,DEJAN PEJIĆ,DANICA MOMČIČEVIĆ,PEĐA KOVAČEVIĆ,MIRKO STANETIĆ,SAŠA DRAGIĆ. Quality of life in lung cancer patients due to treatment. Signa Vitae. 2016. 11(S2);47-50.


1. United States Cancer Statistics (USCS) [Internet]. United States Cancer Statistics. [cited 5ADAD]. Available from: http://nccd.cdc. gov/uscs/

2. [Internet]. [cited 5ADAD]. Available from:

3. American Lung Association ® [Internet]. American Lung Association. [cited 5ADAD]. Available from:

4. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends. Journal of Thoracic Oncology. 2008;3(8):819–831.

5. Lung carcinoma: its profile and changing trends ... [Internet]. [cited 5ADAD]. Available from:

6. Renata Pinjatela:Neke karakteristike kvalitete života osoba sa i bez malignog oboljenja, hrvatska revija za rehabilitacijska istraživanja. 2008;44 (2):79-98.

7. Camps C, Pozo ND, Blasco A, Blasco P, Sirera R. Importance of Quality of Life in Patients with Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2009;10(2):83–90.

8. Title of measure: European Organization for Research and ... [Internet]. [cited 5ADAD]. Available from:

9. EORTC QLQ scoring manual [Internet]. [cited 5ADAD]. Available from:

10. Cocks K, King MT, Velikova G, St-James MM, Fayers PM, Brown JM. Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology. 2010;29(1):89–96.

11. Journal of Clinical Oncology [Internet]. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life. [cited 5ADAD]. Available from:

12. Isaac M, Curtis JR. Improving quality of life for patients with terminal respiratory disease. Expert Review of Respiratory Medicine. 2009;3(6):597–605.

13. Gralla RJ. Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life. The Oncologist. 2004Jan;9(suppl_6):14–24.

14. Langendijk, J.a, G.p.m Ten Velde, N.k Aaronson, J.m.a De Jong, M.j Muller, and E.f.m Wouters. “Quality of Life after Palliative Ra-diotherapy in Non-small Cell Lung Cancer: A Prospective Study.” International Journal of Radiation Oncology*Biology*Physics 47.1 (2000): 149-155.

15. Wang, Dandan, and Jufang Fu. “Symptom Clusters and Quality of Life in China Patients with Lung Cancer Undergoing Chemo-therapy.” African Health Sciences Afr H. Sci. 14.1 (2014): 49.

16. Ahmet Bircan: Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer. Turkish Repiratory Journal. 2003;4(2):61-66.

17. NCCN antiemesis guidelines [Internet]. Available from:

18. Steven D. Passik: Depression in Cancer Patients: Recognition and Treatment, Medscape Psychiatry & Mental Health eJournal. 1997;2(3).

19. Roila, F., and E. Cortesi. “Quality of Life as a Primary End Point in Oncology.”Annals of Oncology 12.Suppl 3 (2001).

20. Chow, Edward, Nadia Jayne Salvo, Stephanie Hadi, Julie Napolskikh, Philiz Goh, and Emily Sinclair. “Quality of Life Measurement in Cancer Patients Receiving Palliative Radiotherapy for Symptomatic Lung Cancer: A Literature Review.”Current Oncology Curr. Oncol. 16.2 (2009).

21. “Full Text: Quality of Life in Cancer Patients Undergoing Chemotherapy.” Full Text: Quality of Life in Cancer Patients Undergoing Chemotherapy.

22. “Chemotherapy and Supportive Care versus Supportive Care Alone for Advanced Non-small Cell Lung Cancer.” Cochrane Database of Systematic Reviews Reviews (2010).

23. Langendijk JA et al: Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer, J Clin Oncol. 2001 Apr 15;19(8):2123-2133.

24. Wintner, L. M., J. M. Giesinger, A. Zabernigg, M. Sztankay, V. Meraner, G. Pall, W. Hilbe, and B. Holzner. “Quality of Life during Chemotherapy in Lung Cancer Patients: Results across Different Treatment Lines.” Br J Cancer British Journal of Cancer 109.9 (2013): 2301-2308.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time